{"id":"cohort-1-lubiprostone-capsule-fasted","safety":{"commonSideEffects":[{"rate":"29","effect":"Nausea"},{"rate":"12","effect":"Diarrhea"},{"rate":"13","effect":"Abdominal pain"},{"rate":"11","effect":"Headache"},{"rate":"7","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lubiprostone is a selective activator of ClC-2 chloride channels located on the apical membrane of gastrointestinal epithelial cells. By opening these channels, it increases chloride and fluid secretion into the intestinal lumen, which increases stool frequency and alleviates constipation. This mechanism enhances intestinal motility and hydration without systemic absorption or effects on other organ systems.","oneSentence":"Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel motility.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:34.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic idiopathic constipation"},{"name":"Opioid-induced constipation"},{"name":"Irritable bowel syndrome with constipation"}]},"trialDetails":[{"nctId":"NCT03010631","phase":"PHASE3","title":"Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers","status":"COMPLETED","sponsor":"Sucampo Pharma Americas, LLC","startDate":"2016-11-16","conditions":"Healthy Volunteers","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMITIZA®","Treatment A"],"phase":"phase_3","status":"active","brandName":"Cohort 1: Lubiprostone Capsule, Fasted","genericName":"Cohort 1: Lubiprostone Capsule, Fasted","companyName":"Sucampo Pharma Americas, LLC","companyId":"sucampo-pharma-americas-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel motility. Used for Chronic idiopathic constipation, Opioid-induced constipation, Irritable bowel syndrome with constipation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}